Once-Weekly Islatravir and Lenacapavir Demonstrate Noninferiority to Daily B/F/TAF for HIV Suppression
Trial shows weekly islatravir and lenacapavir maintain HIV suppression
A Phase 3 trial confirms that once-weekly islatravir-lenacapavir maintains viral suppression comparable to daily B/F/TAF.
A new once-weekly pill combination showed similar success to daily treatment in keeping HIV levels suppressed for adults with the virus.
Drug-Level Feedback Fails to Boost PrEP Adherence in Ugandan Transgender Women
Counseling and Drug Feedback Show No Change in PrEP Adherence
In a 12-month RCT, drug-level feedback with tailored counseling did not improve PrEP adherence among HIV-negative transgender women in Ugand…
A study in Uganda found that drug-level feedback and tailored counseling did not improve PrEP adherence for HIV-negative transgender women.
Islatravir 60 mg oral qm showed 64.3% adverse event rate compared to 77.1% in comparator
Trial Shows Islatravir Shows Tolerable Safety Profile for HIV Prevention
This Phase 3 randomized trial evaluated islatravir 60 mg oral qm in 494 cisgender men and transgender women at increased risk of HIV-1 expos…
A Phase 3 trial of islatravir for HIV prevention showed the medication was generally well tolerated with fewer reported side effects than th…
Bictegravir-lenacapavir maintains viral suppression with 0.3% difference compared to bictegravir-emtricitabine-tenofovir alafenamide
Trial shows new daily pill option for people with HIV
This Phase 3 randomized controlled trial of 574 virologically suppressed people with HIV-1 found that switching to a bictegravir-lenacapavir…
A new once-daily pill combination shows similar success in keeping the virus under control compared to current standard treatments.
Dual-ART and triple-ART both reduce plasma biomarkers of immune activation and neuronal injury
Dual-ART Therapy Shows Lower Brain Inflammation for People with HIV
This randomized controlled trial of 238 adults initiating ART found that both dual-ART and triple-ART regimens significantly reduced markers…
A new trial shows that a specific dual-drug treatment may lower markers of brain inflammation and injury in adults living with HIV.
Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients
New review shows a specific HIV drug combo may improve cholesterol and kidney health
This systematic literature review and network meta-analysis evaluates bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) against othe…
A large review found that a specific HIV drug combination improved cholesterol and kidney function compared to other common treatments for e…
F/TAF PrEP shows similar HIV incidence to F/TDF in cisgender women but noninferiority not proven
PrEP pill F/TAF shows similar HIV prevention as F/TDF in women
This RCT in 1380 predominantly cisgender women in East and South Africa compared daily oral F/TAF vs F/TDF for HIV PrEP over 6 months. HIV i…
A study in African women found that a newer PrEP pill (F/TAF) prevented HIV at similar rates to the standard pill (F/TDF), but the study was…
Preplanned subanalysis shows comparable viral suppression rates for two dolutegravir-based regimens in antiretroviral-naive people with HIV at week 48
New HIV drug combo shows similar virus control to standard care in people with resistance markers
A preplanned subanalysis of a phase IV study compared dolutegravir plus lamivudine against dolutegravir plus tenofovir disoproxil fumarate w…
A specific HIV drug mix controlled the virus just as well as a standard mix in people with certain resistance markers, offering a potential …
HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
Integrase inhibitor regimen showed non-inferiority and fewer adverse events versus boosted protease inhibitor in advanced HIV
Integrase Inhibitors Show Lower Event Rates Than Boosted Protease Inhibitors in Advanced HIV
This trial compared an integrase inhibitor regimen with a boosted protease inhibitor regimen in therapy-naive adults with advanced HIV disea…
A trial of 447 therapy-naive adults with advanced HIV found fewer drug-related side effects with an integrase inhibitor regimen compared to …
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
Switching HIV drugs showed similar metabolic changes over two years in this real-world study
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks
One Shot Saves You From HIV For Six Months
This Cochrane systematic review and meta-analysis of two randomised controlled trials (8660 participants) compared six-monthly subcutaneous …
A single shot under the skin protects against HIV for six months, solving the daily pill problem for millions at risk.
All emtricitabine Articles
- Once-Weekly Islatravir and Lenacapavir Demonstrate Noninferiority to Daily B/F/TAF for HIV Suppression
- Drug-Level Feedback Fails to Boost PrEP Adherence in Ugandan Transgender Women
- Islatravir 60 mg oral qm showed 64.3% adverse event rate compared to 77.1% in comparator
- Bictegravir-lenacapavir maintains viral suppression with 0.3% difference compared to bictegravir-emtricitabine-tenofovir alafenamide
- Dual-ART and triple-ART both reduce plasma biomarkers of immune activation and neuronal injury
- Bictegravir/emtricitabine/tenofovir alafenamide shows favorable lipid and renal changes versus other regimens in treatment-experienced HIV-1 patients
- F/TAF PrEP shows similar HIV incidence to F/TDF in cisgender women but noninferiority not proven
- Preplanned subanalysis shows comparable viral suppression rates for two dolutegravir-based regimens in antiretroviral-naive people with HIV at week 48
- Integrase inhibitor regimen showed non-inferiority and fewer adverse events versus boosted protease inhibitor in advanced HIV
- HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
- Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
- Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks
- CDC updates recommendations for HIV nonoccupational postexposure prophylaxis
- Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1